Contact
29 Jan 26
News
29 Jan 26

Biocomposites launches SYNICEM™ spacers in Canada

Ready-to-use preformed antibiotic loaded spacers for hip, knee and shoulder revisions

Choice of Charnley and Müller hip spacer designs, and left and right geometries for each knee

Keele, UK, 29 January 2026 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the launch of its SYNICEM™ hip, knee and shoulder preformed spacers in Canada.

SYNICEM™ antibiotic loaded preformed spacers are designed to preserve articular space, limb length and joint stability during two-stage revision procedures, while aiding in the treatment of infection by bacteria sensitive to gentamicin. Precision-engineered for consistency and structural uniformity, they are sterile, ready-to-use in under a minute, and reduce the time demands and mechanical risks associated with traditional intra-operative molded or handmade spacers.

Available in a comprehensive range of sizes and styles for case-by-case flexibility, the SYNICEM™ spacer range includes a choice of Charnley and Müller hip spacer designs, and specific left and right geometries for each knee. SYNICEM™ spacers have been successfully used for more than 20 years in over 70 countries, helping surgeons save operative time and manage challenging infection cases.

Michael Harris, Chief Executive Officer of Biocomposites, said: “Making SYNICEM™ preformed antibiotic loaded spacers available to surgeons in Canada, less than three months after launching them in the U.S., is a source of pride for the team at Biocomposites. The quality and consistency of the SYNICEM™ spacer range reflects our long-standing focus on precision engineering and dependable performance, with the aim of supporting clinicians and improving care for patients with complex needs.”

Contact for Media enquiries

Optimum Strategic Communications

Mary Clark, Stephen Adams, Katie Flint, Nellie Stephens
Tel: +44 (0)20 3922 1906
biocomposites@optimumcomms.com

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, South America, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites’ products are now used in over 1 million procedures per annum and sold in more than 100 countries around the world. In January 2026 Biocomposites was named as one of the UK’s 100 fastest growing technology companies by The Sunday Times. See here for The Sunday Times’ 100 Tech 2026 list. Please visit biocomposites.com to learn more.

About SYNICEMTM bone cements

SYNICEMTM bone cements have been developed to provide the ideal interface between prosthesis and bone – optimised to provide secure and stable fixation for joint replacement surgery, including between irregular bone surfaces and the prosthesis. SYNICEMTM bone cements are manufactured in-house under strictly controlled conditions using out proprietary process. The SYNICEMTM bone cement range includes cements loaded with gentamicin (an antibiotic) for revision procedures in patients at high risk of infection due to gentamicin-sensitive bacteria and patients with compromised immunity. SYNICEMTM bone cements are already used in more than 100 countries around the world.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties


Visit our News & Events page

Library

Interested in other types of our content? See a list of some of our most recent below.

Explore Library